Market Overview:Recombinant erythropoietin products are utilized to treat anemia conditions caused due to renal diseases, cancer, HIV/AIDS, and other chronic illnesses. The recombinant erythropoietin stimulates the bone marrow to produce more red blood cells, which help in improvement of oxygen delivery in the body. Major types of recombinant erythropoietin products available in the market are...
Content: The global Recombinant Erythropoietin Market is estimated to be valued at US$ 7.01 billion in 2023 and is expected to exhibit a CAGR of 2% over the forecast period of 2023-2030, as highlighted in a new report published by Coherent Market Insights.Market Overview:Recombinant Erythropoietin, also known as EPO, is a synthetic version of the natural hormone erythropoietin, which stimulates...
Recombinant erythropoietin is a prescription drug used to treat anemia in people with kidney disease and certain other conditions. It works by stimulating the bone marrow to produce more red blood cells.
The global recombinant erythropoietin market is estimated to be valued at US$ 6.2 Bn in 2024 and is expected to exhibit a CAGR of 3.4% over the forecast period 2024-2031, as highlighted in a...